|
Pharmacology
Citations 101-110 of 165 total displayed.
|
Past content
(since Dec 2002):
|
- CLINICAL
Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis
- S. Adler, S. Lodermeyer, J. Gaa, and U. Heemann
Rheumatology 2008; 47: 1535-1538.
[Abstract]
[Full Text]
- CLINICAL
Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States
- T. Sokka and T. Pincus
Rheumatology 2008; 47: 1543-1547.
[Abstract]
[Full Text]
- CLINICAL
Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis
- L. H. D. van Tuyl, A. M. C. Plass, W. F. Lems, A. E. Voskuyl, P. J. S. M. Kerstens, B. A. C. Dijkmans, and M. Boers
Rheumatology 2008; 47: 1571-1576.
[Abstract]
[Full Text]
[ Supplementary Data ]
- LETTERS TO THE EDITOR
BSR DMARD monitoring guidelines: sulfasalazine
- P. Jobanputra
Rheumatology 2008; 47: 1587-a--a1588.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance
- G. Kobelt
Rheumatology 2008; 47: 1589-1590.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
- A. Wailoo, N. Bansback, and J. Chilcott
Rheumatology 2008; 47: 1590-a.
[Extract]
[Full Text]
- MATTERS ARISING
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: Editor's note
- Editor
Rheumatology 2008; 47: 1590-1591.
[Extract]
[Full Text]
- EDITORIALS
Safer NSAID strategies: consensus or contentious?
- C. J. Hawkey
Rheumatology 2008; 47: 1265-1266.
[Extract]
[Full Text]
- EDITORIALS
Issues with vitamin D in routine clinical practice
- B. J. Jones and P. J. Twomey
Rheumatology 2008; 47: 1267-1268.
[Extract]
[Full Text]
- CLINICAL
Use of NSAIDs and infection with Helicobacter pylori—what does the rheumatologist need to know?
- U. Kiltz, J. Zochling, W. E. Schmidt, and J. Braun
Rheumatology 2008; 47: 1342-1347.
[Abstract]
[Full Text]
|
|
